173 related articles for article (PubMed ID: 22227588)
21. Resistance considerations in sequencing of antiretroviral therapy in low-middle income countries with currently available options.
De Luca A; Prosperi M; Bracciale L
Curr Opin HIV AIDS; 2010 Jan; 5(1):27-37. PubMed ID: 20046145
[TBL] [Abstract][Full Text] [Related]
22. Resistance profiles after different periods of exposure to a first-line antiretroviral regimen in a Cameroonian cohort of HIV type-1-infected patients.
Soria A; Porten K; Fampou-Toundji JC; Galli L; Mougnutou R; Buard V; Kfutwah A; Vessière A; Rousset D; Teck R; Calmy A; Ciaffi L; Lazzarin A; Gianotti N
Antivir Ther; 2009; 14(3):339-47. PubMed ID: 19474468
[TBL] [Abstract][Full Text] [Related]
23. Treatment initiation with zidovudine-containing potent antiretroviral therapy impairs CD4 cell count recovery but not clinical efficacy.
Huttner AC; Kaufmann GR; Battegay M; Weber R; Opravil M
AIDS; 2007 May; 21(8):939-46. PubMed ID: 17457087
[TBL] [Abstract][Full Text] [Related]
24. Efficacy and safety of once-daily combination therapy with didanosine, lamivudine and nevirapine in antiretroviral-naive HIV-infected patients.
Ribera E; Rodríguez-Pardo D; Rubio M; Soler A; Pedrol E; Blanco JL; González A; Crespo M; Falcó V; Ocaña I; Deig E; Miró JM; Pahissa A
Antivir Ther; 2005; 10(5):605-14. PubMed ID: 16152754
[TBL] [Abstract][Full Text] [Related]
25. Increasing prevalence of transmitted drug resistance mutations and non-B subtype circulation in antiretroviral-naive chronically HIV-infected patients from 2001 to 2006/2007 in France.
Descamps D; Chaix ML; Montes B; Pakianather S; Charpentier C; Storto A; Barin F; Dos Santos G; Krivine A; Delaugerre C; Izopet J; Marcelin AG; Maillard A; Morand-Joubert L; Pallier C; Plantier JC; Tamalet C; Cottalorda J; Desbois D; Calvez V; Brun-Vezinet F; Masquelier B; Costagliola D;
J Antimicrob Chemother; 2010 Dec; 65(12):2620-7. PubMed ID: 20965891
[TBL] [Abstract][Full Text] [Related]
26. When to start antiretroviral therapy?
Wilkin TJ; Gulick RM
Clin Infect Dis; 2008 Dec; 47(12):1580-6. PubMed ID: 18990069
[TBL] [Abstract][Full Text] [Related]
27. [Epidemiology of primary drug resistance in chronically HIV-infected patients in Nordrhein-Westfalen, Germany, 2001-2005].
Oette M; Kaiser R; Däumer M; Fätkenheuer G; Rockstroh JK; Knechten H; Mitrenga D; Beerenwinkel N; Sagir A; Pfister H; Häussinger D
Dtsch Med Wochenschr; 2007 May; 132(18):977-82. PubMed ID: 17457780
[TBL] [Abstract][Full Text] [Related]
28. Assessing adherence to antiretroviral therapy in randomized HIV clinical trials: a review of currently used methods.
Marcellin F; Spire B; Carrieri MP; Roux P
Expert Rev Anti Infect Ther; 2013 Mar; 11(3):239-50. PubMed ID: 23458765
[TBL] [Abstract][Full Text] [Related]
29. Antiretroviral therapy adherence and drug-drug interactions in the aging HIV population.
Nachega JB; Hsu AJ; Uthman OA; Spinewine A; Pham PA
AIDS; 2012 Jul; 26 Suppl 1():S39-53. PubMed ID: 22781176
[TBL] [Abstract][Full Text] [Related]
30. Population uptake and effectiveness of test-and-treat antiretroviral therapy guidelines for preventing the global spread of HIV: an ecological cross-national analysis.
Mendez-Lopez A; McKee M; Stuckler D; Granich R; Gupta S; Noori T; Semenza JC
HIV Med; 2019 Sep; 20(8):501-512. PubMed ID: 31140715
[TBL] [Abstract][Full Text] [Related]
31. Transmitted HIV drug resistance in Asia.
Sohn AH; Srikantiah P; Sungkanuparph S; Zhang F
Curr Opin HIV AIDS; 2013 Jan; 8(1):27-33. PubMed ID: 23196932
[TBL] [Abstract][Full Text] [Related]
32. Differential associations between perceived and objective measurement of distress tolerance in relation to antiretroviral treatment adherence and response among HIV-positive individuals.
Oser ML; Trafton JA; Lejuez CW; Bonn-Miller MO
Behav Ther; 2013 Sep; 44(3):432-42. PubMed ID: 23768670
[TBL] [Abstract][Full Text] [Related]
33. Nested model reveals potential amplification of an HIV epidemic due to drug resistance.
Saenz RA; Bonhoeffer S
Epidemics; 2013 Mar; 5(1):34-43. PubMed ID: 23438429
[TBL] [Abstract][Full Text] [Related]
34. Interventions to improve the performance of HIV health systems for treatment-as-prevention in sub-Saharan Africa: the experimental evidence.
Bärnighausen T; Tanser F; Dabis F; Newell ML
Curr Opin HIV AIDS; 2012 Mar; 7(2):140-50. PubMed ID: 22248917
[TBL] [Abstract][Full Text] [Related]
35. Antiretroviral therapy for prevention of HIV transmission: potential role for people who inject drugs in Central Asia.
McNairy ML; Deryabina A; Hoos D; El-Sadr WM
Drug Alcohol Depend; 2013 Nov; 132 Suppl 1():S65-70. PubMed ID: 23880248
[TBL] [Abstract][Full Text] [Related]
36. Suboptimal plasma HIV-1 RNA suppression and adherence among sex workers who use illicit drugs in a Canadian setting: an observational cohort study.
Ti L; Milloy MJ; Shannon K; Simo A; Hogg RS; Guillemi S; Montaner J; Kerr T; Wood E
Sex Transm Infect; 2014 Aug; 90(5):418-22. PubMed ID: 24523347
[TBL] [Abstract][Full Text] [Related]
37. Patching a leaky pipe: the cascade of HIV care.
Kilmarx PH; Mutasa-Apollo T
Curr Opin HIV AIDS; 2013 Jan; 8(1):59-64. PubMed ID: 23211779
[TBL] [Abstract][Full Text] [Related]
38. 'Test-and-treat': the end of the HIV epidemic?
Cambiano V; Rodger AJ; Phillips AN
Curr Opin Infect Dis; 2011 Feb; 24(1):19-26. PubMed ID: 21157329
[TBL] [Abstract][Full Text] [Related]
39. HIV treatment as prevention and HPTN 052.
Cohen MS; McCauley M; Gamble TR
Curr Opin HIV AIDS; 2012 Mar; 7(2):99-105. PubMed ID: 22227585
[TBL] [Abstract][Full Text] [Related]
40. Using electronic drug monitor feedback to improve adherence to antiretroviral therapy among HIV-positive patients in China.
Sabin LL; DeSilva MB; Hamer DH; Xu K; Zhang J; Li T; Wilson IB; Gill CJ
AIDS Behav; 2010 Jun; 14(3):580-9. PubMed ID: 19771504
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
